ChemicalBook > CAS DataBase List > CC 930

CC 930

Product Name
CC 930
CAS No.
899805-25-5
Chemical Name
CC 930
Synonyms
CC930;CC 930;MCC930;CC-930;CS-1152;Tanziser;Tanzisertib;CC-930(Tanzisertib);TANZISERTIB (CC-930);TANZISERTIB; CC930; CC 930
CBNumber
CB12666607
Molecular Formula
C21H23F3N6O2
Formula Weight
448.44
MOL File
899805-25-5.mol
More
Less

CC 930 Property

Boiling point:
626.4±65.0 °C(Predicted)
Density 
1.63±0.1 g/cm3(Predicted)
storage temp. 
Store at -20°C
solubility 
Soluble in DMSO
form 
Powder
pka
15.05±0.40(Predicted)
color 
Off-white to yellow
More
Less

Hazard and Precautionary Statements (GHS)

Symbol(GHS)
Signal word
Warning
Hazard statements

H302Harmful if swallowed

Precautionary statements

P280Wear protective gloves/protective clothing/eye protection/face protection.

P305+P351+P338IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continuerinsing.

More
Less

N-Bromosuccinimide Price

Cayman Chemical
Product number
22466
Product name
CC-930
Purity
≥98%
Packaging
1mg
Price
$36
Updated
2024/03/01
Cayman Chemical
Product number
22466
Product name
CC-930
Purity
≥98%
Packaging
5mg
Price
$155
Updated
2024/03/01
Cayman Chemical
Product number
22466
Product name
CC-930
Purity
≥98%
Packaging
10mg
Price
$274
Updated
2024/03/01
Cayman Chemical
Product number
22466
Product name
CC-930
Purity
≥98%
Packaging
25mg
Price
$595
Updated
2024/03/01
TRC
Product number
T007100
Product name
Tanzisertib
Packaging
5mg
Price
$150
Updated
2021/12/16
More
Less

CC 930 Chemical Properties,Usage,Production

Uses

Tanzisertib is a potent, selective, and orally active c-Jun amino-terminal kinase (JNK) inhibitor used for treatment of dermal fibrosis.

Biological Activity

Tanzisertib (CC-930, JNK-930, JNKI-1) has an ATP-competitive inhibitory effect on the phosphorylation of the JNK-dependent protein substrate c-Jun and all isoforms of JNK (Ki(JNK1) = 44 ± 3 nM, IC50(JNK1) = 61 nM, Ki(JNK2) = 6.2 ± 0.6 nM, IC50(JNK2) = 5 nM, IC50(JNK3) = 5 nM), selective inhibition of ERK1 and p38a with IC50 of 0.48 μM and 3.4 μM, respectively .

in vivo

In the acute PK-PD rat model of LPS-induced TNFα production, oral administration of 10 mg/kg and 30 mg/kg of CC-930 reduced the production of TNFα in vivo by 23% and 77%, respectively. CC-930 is well tolerated in vivo and its effect is proportional to dose.

target

< td style="border-bottom: 1px dotted #ccc;padding: 5px;"> JNK1
(Cell-free assay)
TargetValue
JNK3
(Cell-free assay)		 0.006 μM
JNK2
(Cell-free assay)		 0.007 μM
0.061 μM

CC 930 Preparation Products And Raw materials

Raw materials

Preparation Products

More
Less

CC 930 Suppliers

China 66 China Hong Kong 1 India 2 United Kingdom 1 United States 12 Global 82
Sequoia Research Products Ltd.
Tel
--
Fax
--
Email
sales@seqchem.com
Country
United Kingdom
ProdList
3113
Advantage
69

899805-25-5, CC 930Related Search:


  • MCC930
  • CC 930
  • CC930
  • CC-930
  • Tanzisertib
  • trans-4-[[9-[(3S)-Tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]cyclohexanol
  • 4-[[9-[(3s)-oxolan-3-yl]-8-(2,4,6-trifluoroanilino)purin-2-yl]amino]cyclohexan-1-ol
  • TANZISERTIB (CC-930)
  • Tanzisertib(CC-930) (free base)
  • TANZISERTIB; CC930; CC 930
  • CC-930(Tanzisertib)
  • CS-1152
  • Cyclohexanol, 4-[[9-[(3S)-tetrahydro-3-furanyl]-8-[(2,4,6-trifluorophenyl)amino]-9H-purin-2-yl]amino]-, trans-
  • trans-4-((9-((S)-tetrahydrofuran-3-yl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)cyclohexanol
  • Tanzisertib,Inhibitor,inhibit,CC 930,CC930,JNK
  • Tanziser
  • 899805-25-5
  • C21H23F3N6O2
  • MAPK